FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282968781> ?p ?o ?g. }

• W4282968781 endingPage "4196" @default.
• W4282968781 startingPage "4196" @default.
• W4282968781 abstract "Abstract Identifying how to optimally combine immunotherapies with other available anti-cancer therapies is a major challenge in oncology. We have utilized an implantable microdevice performing cassette microdosing that measures intratumor drug responses and anti-tumor immunity for eleven agents in parallel. Local tumor response is measured by cyclical immunofluorescence for deep cellular response phenotyping. This approach is combined with the systemic administration of checkpoint inhibitors to examine whether local immunogenic cell death (ICD) induced by a given drug microdose potentiates the immunotherapy’s anti-tumor effect. The measurements were performed in a humanized mouse model of clear cell renal cancer, patient derived xenograft (PDX) RXF488. RXF488 was implanted subcutaneously in 30 NSG mice. Animals were stratified into 6 groups with n= 4-6. Humanization was performed by the intravenous injection of 5x10e6 human peripheral blood mononuclear cells prior to the first treatment. Systemic anti-PD1 treatment was applied in the presence and absence of the microdevice loaded with eleven different drugs. Control groups received the empty microdevice in the presence or absence of PBMC. Beside the histological examination of the tumor tissue, flow cytometry (FC) was performed on bone marrow, spleen and tumor tissue to determine infiltration of human immune cells. FC analyses revealed no influence of the treatment on the human immune cells in bone marrow and spleen. The anti-PD1 treatment induced an increase in huCD45+ cells specifically in the tumor tissue only 48h after treatment. Several agents showed a significant increase in apoptosis induction when nivolumab was added: The largest increase was observed for the panRAF inhibitor LXH254, Sorafenib, Oxaliplatin and Doxorubicin. The increased efficacy from immunotherapy administration has a strong positive correlation with increased induction of ICD in the tumor microenvironment determined by CD11b, ICAM-1 and MHC-II expression: drugs that showed the highest increase in apoptosis when combined with aPD-1 showed an increased likelihood for markers associated with ICD, namely Oxaliplatin and LXH254. We were able to verify the results of the screening experiment in a conventional setting with systemic combination treatment arms in the same PDX model. Our results demonstrate that local tumor response signatures of ICD can be used to systemically identify synergistic combinations of a range of drugs with immunotherapy on a tumor specific basis. The approach may represent a new paradigm for efficient in vivo screening of novel combinations, particularly with combinations involving immunotherapies. Citation Format: Oliver Jonas, Eva Oswald, Kanstantsin Lashuk, Sebastian Ahn, Julia Schüler. A controlled drug release device facilitates the identification of favorable combinations of immune-oncology drugs with targeted or cytotoxic drugs in a patient-derived humanized mouse model of renal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4196." @default.
• W4282968781 created "2022-06-17" @default.
• W4282968781 creator A5014860176 @default.
• W4282968781 creator A5016088356 @default.
• W4282968781 creator A5034493142 @default.
• W4282968781 creator A5038626233 @default.
• W4282968781 creator A5088738771 @default.
• W4282968781 date "2022-06-15" @default.
• W4282968781 modified "2023-09-24" @default.
• W4282968781 title "Abstract 4196: A controlled drug release device facilitates the identification of favorable combinations of immune-oncology drugs with targeted or cytotoxic drugs in a patient-derived humanized mouse model of renal cancer" @default.
• W4282968781 doi "https://doi.org/10.1158/1538-7445.am2022-4196" @default.
• W4282968781 hasPublicationYear "2022" @default.
• W4282968781 type Work @default.
• W4282968781 citedByCount "0" @default.
• W4282968781 crossrefType "journal-article" @default.
• W4282968781 hasAuthorship W4282968781A5014860176 @default.
• W4282968781 hasAuthorship W4282968781A5016088356 @default.
• W4282968781 hasAuthorship W4282968781A5034493142 @default.
• W4282968781 hasAuthorship W4282968781A5038626233 @default.
• W4282968781 hasAuthorship W4282968781A5088738771 @default.
• W4282968781 hasConcept C121608353 @default.
• W4282968781 hasConcept C126322002 @default.
• W4282968781 hasConcept C137061746 @default.
• W4282968781 hasConcept C154317977 @default.
• W4282968781 hasConcept C202751555 @default.
• W4282968781 hasConcept C203014093 @default.
• W4282968781 hasConcept C2777701055 @default.
• W4282968781 hasConcept C2780007613 @default.
• W4282968781 hasConcept C2780030458 @default.
• W4282968781 hasConcept C2780674031 @default.
• W4282968781 hasConcept C2780851360 @default.
• W4282968781 hasConcept C2780931953 @default.
• W4282968781 hasConcept C502942594 @default.
• W4282968781 hasConcept C55493867 @default.
• W4282968781 hasConcept C71924100 @default.
• W4282968781 hasConcept C86803240 @default.
• W4282968781 hasConcept C8891405 @default.
• W4282968781 hasConcept C96232424 @default.
• W4282968781 hasConcept C98274493 @default.
• W4282968781 hasConceptScore W4282968781C121608353 @default.
• W4282968781 hasConceptScore W4282968781C126322002 @default.
• W4282968781 hasConceptScore W4282968781C137061746 @default.
• W4282968781 hasConceptScore W4282968781C154317977 @default.
• W4282968781 hasConceptScore W4282968781C202751555 @default.
• W4282968781 hasConceptScore W4282968781C203014093 @default.
• W4282968781 hasConceptScore W4282968781C2777701055 @default.
• W4282968781 hasConceptScore W4282968781C2780007613 @default.
• W4282968781 hasConceptScore W4282968781C2780030458 @default.
• W4282968781 hasConceptScore W4282968781C2780674031 @default.
• W4282968781 hasConceptScore W4282968781C2780851360 @default.
• W4282968781 hasConceptScore W4282968781C2780931953 @default.
• W4282968781 hasConceptScore W4282968781C502942594 @default.
• W4282968781 hasConceptScore W4282968781C55493867 @default.
• W4282968781 hasConceptScore W4282968781C71924100 @default.
• W4282968781 hasConceptScore W4282968781C86803240 @default.
• W4282968781 hasConceptScore W4282968781C8891405 @default.
• W4282968781 hasConceptScore W4282968781C96232424 @default.
• W4282968781 hasConceptScore W4282968781C98274493 @default.
• W4282968781 hasIssue "12_Supplement" @default.
• W4282968781 hasLocation W42829687811 @default.
• W4282968781 hasOpenAccess W4282968781 @default.
• W4282968781 hasPrimaryLocation W42829687811 @default.
• W4282968781 hasRelatedWork W2318567272 @default.
• W4282968781 hasRelatedWork W2763883091 @default.
• W4282968781 hasRelatedWork W2979186475 @default.
• W4282968781 hasRelatedWork W3180780036 @default.
• W4282968781 hasRelatedWork W4220665865 @default.
• W4282968781 hasRelatedWork W4291367166 @default.
• W4282968781 hasRelatedWork W4294940896 @default.
• W4282968781 hasRelatedWork W4311194870 @default.
• W4282968781 hasRelatedWork W4360983034 @default.
• W4282968781 hasRelatedWork W4378715746 @default.
• W4282968781 hasVolume "82" @default.
• W4282968781 isParatext "false" @default.
• W4282968781 isRetracted "false" @default.
• W4282968781 workType "article" @default.